Results 61 to 70 of about 305,562 (334)
Journal of Hepatocellular Carcinoma, 2023 Ali Riza Koksal,1 Nergiz Ekmen,2 Yucel Aydin,2 Kelley Nunez,3 Tyler Sandow,4 Molly Delk,2 Martin Moehlen,2 Paul Thevenot,3 Ari Cohen,3,5 Srikanta Dash1,2,6 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New ...
Koksal AR +9 more
doaj
Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC [PDF]
, 2023 Rong Wen +8 more
openalex +1 more source
Advanced Functional Materials, EarlyView.The cGAS‐STING pathway boosts HCC antitumor immunity but lacks specific activation. Nanoplatform ZMRPF induces HCC ferroptosis via lipid ROS, releasing mtDNA. It synergizes with ZMRPF‐released Mn2⁺ to activate cGAS‐STING, amplifies antigen‐presenting cell activity, reverses HCC immunosuppression, and enables robust systemic antitumor immunity ...
Yuchen Zhang +13 more
wiley +1 more source
Медицинский совет, 2021 Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported ...
I. А. Dzhanyan +2 more
doaj +1 more source
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]
, 2018 It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P +5 more
core +1 more source
Synthetic Nanobiology Actuated Lipometabolic Cell Factory for Autologous Tumor Immunotherapy
Advanced Functional Materials, EarlyView.FA plays a crucial role in the interaction between tumor cells and the tumor microenvironment, especially for the immune response. A biocatalytic immunoenhancement strategy is developed to boost antitumor immunity by FA metabolic orientation to ceramide. Through the design of this delicate catalytic immunoenhancement strategy, the synthetic nanobiology
Shoujie Zhao +8 more
wiley +1 more source
Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]
, 2015 Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján +2 more
core +1 more source
Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk
Advanced Healthcare Materials, EarlyView.Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor +12 more
wiley +1 more source
Zhongliu Fangzhi Yanjiu, 2020 Objective To investigate the expressions of Mina53 and CBX8 in hepatocellular carcinoma (HCC), and to analyze their correlation with the clinicopathological features and prognosis of HCC patients.
YE Dongxue +5 more
doaj +1 more source
Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease
Immunological Medicine, 2021 Non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) are becoming major liver diseases worldwide. Liver fibrosis and cirrhosis are among the most significant risk factors of hepatocellular carcinoma (HCC) and associated with the long-term ...
Sachiyo Yoshio, Tatsuya Kanto
doaj +1 more source